We are international
trials TEXT SIZE   

EMPLICITI (elotuzumab) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone, in people who have received one to three prior treatments for their multiple myeloma.

Unlike traditional chemotherapy treatments, EMPLICITI is a new type of immunotherapy that works with a patient’s own immune system to fight multiple myeloma. EMPLICITI works in 2 ways. It activates a key type of white blood cell in your immune system, called a Natural Killer (NK) Cell. EMPLICITI also identifies myeloma cells so they are more easily recognized by NK Cells. That way, activated NK Cells can find myeloma cells to destroy.

General Information
Clinical Trials
News & Press Releases